TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11495488

Group type: EXPERIMENTAL
Intervention: Nebulized amikacin treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single urine assay for monitoring nebulized amikacin
Number of subjects: 37
Study: 9565507

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MUGA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study: 7755480

Group type: EXPERIMENTAL
Intervention: Captopril, 75 mg a day (n = 8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 13
Study: 2472126

Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (100 to 200 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study: 8180714

Group type: EXPERIMENTAL
Intervention: Health fair, health risk information, follow-up screening, and incentive program (five $100 cash prizes for reducing serum cholesterol levels by 20% or below 5.17 mmol/L)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Health fair, health risk information, and follow-up screening (no incentive program)
Number of subjects: 63
Study: 762369

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine 6 mg daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dihydroergotoxine 3 mg daily
Number of subjects: 14
Study: 31291879

Group type: EXPERIMENTAL
Intervention: Preoperative breathing exercises (deep breathing, cough, and incentive spirometer)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital routine physiotherapy (control group)
Number of subjects: 100
Study: 29037640

Group type: EXPERIMENTAL
Intervention: Movement control exercises
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups (Movement control and Stabilization)
Number of subjects: 32
Study: 25886131

Group type: EXPERIMENTAL
Intervention: Safety interventions (two arms)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 36
Study: 24377218

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy of regulating qi circulation of fu-organ
Number of subjects: 75

Group type: COMPARATOR
Intervention: Shengxue Tongbian Capsules
Number of subjects: 75
Study: 20639765

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 666

Group type: COMPARATOR
Intervention: Double-bolus eptifibatide
Number of subjects: 666
Study: 19139435

Group type: EXPERIMENTAL
Intervention: Methotrexate 1 g/m2 over 24 hours with intrathecal injection and folinic acid rescue at 42 hours (MTX1 arm)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Methotrexate 3 g/m2 over 3 hours without intrathecal injection and folinic acid rescue at 24 hours (MTX3 arm)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Methotrexate 1 g/m2 over 24 hours (MTX1 arm)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Methotrexate 3 g/m2 over 3 hours (MTX3 arm)
Number of subjects: 352
Study: 17703713

Group type: EXPERIMENTAL
Intervention: Bridges intervention (Standard Treatment plus Bridges)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard Treatment with Attention Control
Number of subjects: 18
Study: 15073108

Group type: EXPERIMENTAL
Intervention: Ro 09‐4889 (1-200 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ro 09‐4889 (20 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ro 09‐4889
Number of subjects: 64
Study: 11455810

Group type: EXPERIMENTAL
Intervention: Misoprostol 600 micrograms orally
Number of subjects: 0
Study: 9603112

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7906814

Group type: EXPERIMENTAL
Intervention: Echo‐planar imaging (EPI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ultrasound measurements
Number of subjects: 11
Study: 3136639

Group type: EXPERIMENTAL
Intervention: Adjunctive enteral supplements
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 22
Study: 31841106

Group type: EXPERIMENTAL
Intervention: Test formulation (generic from Panacea)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Reference formulation (innovator from Astellas)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 56
Study: 31165950

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 80
Study: 28118938

Group type: EXPERIMENTAL
Intervention: PIKA vaccine accelerated regimen
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PIKA vaccine classic regimen
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control vaccine classic regimen
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PIKA vaccine
Number of subjects: 37
Study: 24834925

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 or 10 mg/kg every 4 weeks)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 163
Study: 23399108

Group type: EXPERIMENTAL
Intervention: Gland-preserving surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical excision of the entire gland
Number of subjects: 40
Study: 21705958

Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented group (LF)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Control formula group (CF)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Breastfed group (BF)
Number of subjects: 473
Study: 20035630

Group type: EXPERIMENTAL
Intervention: Standard quality control program (QCP) for acupuncture trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality assurance and monitoring by appointed monitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular meetings for performance improvement
Number of subjects: 0
Study: 16847400

Group type: COMPARATOR
Intervention: R‐/S‐bicalutamide/HP55S 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: R‐bicalutamide/HP55S 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: R‐bicalutamide/HP55S 450 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R‐bicalutamide/HP55S
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R‐/S‐bicalutamide/HP55S
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R‐bicalutamide/HP55S and R‐/S‐bicalutamide/HP55S
Number of subjects: 0
Study: 12490770

Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/day)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg/day)
Number of subjects: 123
Study: 11571221

Group type: EXPERIMENTAL
Intervention: Tourette's syndrome subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9670800

Group type: EXPERIMENTAL
Intervention: self‐exposure in vivo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: self‐exposure in vivo with cognitive therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: waiting‐list control group
Number of subjects: 71
Study: 8110552

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen
Number of subjects: 139

Group type: COMPARATOR
Intervention: Air-oxygen
Number of subjects: 139
Study: 3198362

Group type: EXPERIMENTAL
Intervention: 0.25 mmol Gd-DTPA/kg body weight
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.5 ml 0.9% saline/kg body weight (control)
Number of subjects: 12
Study: 30822414

Group type: EXPERIMENTAL
Intervention: Topical Epigallocatechin-3-Gallate (EGCG)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Topical Epigallocatechin-3-Gallate (EGCG) by zonal priming
Number of subjects: 62
Study: 28263374

Group type: EXPERIMENTAL
Intervention: Nurse‐led multidomain intervention targeting cardiovascular risk factors to prevent dementia
Number of subjects: 2994

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2994
Study: 26328470

Group type: EXPERIMENTAL
Intervention: Quercetin (162 mg/d from onion skin extract)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23684680

Group type: EXPERIMENTAL
Intervention: TV-in-TV
Number of subjects: 2554

Group type: EXPERIMENTAL
Intervention: TVE
Number of subjects: 2554
Study: 24363694

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 micrograms every 4 hours, up to 6 doses)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Foley catheter (18 F, inflated with 50 cc of sterile water)
Number of subjects: 108
Study: 19692661

Group type: EXPERIMENTAL
Intervention: Resistance exercise (8 x 5 leg extension, 80% 1-RM) followed by repeated sprints (10 x 6 s, 0.75 Nxm torque/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Repeated sprints followed by resistance exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Both exercise orders
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Resistance exercise followed by repeated sprints
Number of subjects: 6
Study: 20425365

Group type: EXPERIMENTAL
Intervention: BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 0
Study: 14687097

Group type: EXPERIMENTAL
Intervention: Bougie held at 20 cm from the tip
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bougie held at 30 cm from the tip
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single-use bougie
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple-use bougie
Number of subjects: 50
Study: 11761469

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9141933

Group type: EXPERIMENTAL
Intervention: Lumbar epidural lidocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lumbar epidural saline
Number of subjects: 8
Study: 8405525

Group type: EXPERIMENTAL
Intervention: Nal-Lys (25 micrograms/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nal-Lys (50 micrograms/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nal-Lys (0 micrograms/kg)
Number of subjects: 7
Study: 3769897

Group type: EXPERIMENTAL
Intervention: Doxapram (3 mg kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Almitrine (1 mg kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30403006

Group type: EXPERIMENTAL
Intervention: Standardized automated clinic blood pressure measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bundled standardization intervention
Number of subjects: 0
Study: 26927909

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 455
Study: 23886411

Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein (hCAS) protein meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey (hWHEY) protein meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrolyzed casein (hCAS) and hydrolyzed whey (hWHEY) protein meals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Leucine co-ingestion
Number of subjects: 12
Study: 22575166

Group type: EXPERIMENTAL
Intervention: FLU-v low dose (250 μg) adjuvanted
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FLU-v high dose (500 μg) adjuvanted
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FLU-v (both doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FLU-v (all formulations)
Number of subjects: 48
Study: 20307800

Group type: EXPERIMENTAL
Intervention: Detoxification program characteristics (accreditation, fewer beds, longer stays, shorter distance between detoxification and outpatient unit, larger city population)
Number of subjects: 632
Study: 18852411

Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy with home reinforcement (OBVAT)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Home-based pencil push-ups (HBPP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Office-based placebo therapy with home reinforcement (OBPT)
Number of subjects: 221
Study: 15909196

Group type: EXPERIMENTAL
Intervention: CT with IV contrast agent
Number of subjects: 19

Group type: COMPARATOR
Intervention: CT without IV contrast agent
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clinical evaluation by two specialists
Number of subjects: 19
Study: 12206610

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bovine thrombin (T)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pressure (P)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bovine thrombin-soaked cellulose sponges (TG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose (S)
Number of subjects: 28
Study: 10612136

Group type: EXPERIMENTAL
Intervention: Ho-Yag laser
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mechanical meniscectomy
Number of subjects: 76
Study: 7717281

Group type: EXPERIMENTAL
Intervention: Losartan potassium
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: Losartan monotherapy
Number of subjects: 2900

Group type: EXPERIMENTAL
Intervention: Losartan + Hydrochlorothiazide
Number of subjects: 2900
Study: 2045618

Group type: EXPERIMENTAL
Intervention: Facilitated referral to an asthma specialist
Number of subjects: 309

Group type: COMPARATOR
Intervention: Continued outpatient management from generalist physicians
Number of subjects: 309
Study: 6516811

Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (0.25 ml 0.9% NaCl)
Number of subjects: 27
Study: 29410014

Group type: EXPERIMENTAL
Intervention: 4 mg of baricitinib
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 2 mg of baricitinib
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 28478725

Group type: EXPERIMENTAL
Intervention: Head CT examination
Number of subjects: 147

Group type: COMPARATOR
Intervention: In-hospital observation
Number of subjects: 147
Study: 26207537

Group type: EXPERIMENTAL
Intervention: DIEP group (classical DIEP flap using 1 venous anastomosis)
Number of subjects: 52

Group type: COMPARATOR
Intervention: DIEP-TAsc group (thoracoacromial venous supercharged DIEP flap using the ipsilateral superficial epigastric vein)
Number of subjects: 52
Study: 24892803

Group type: EXPERIMENTAL
Intervention: Composite Variability Index (CVI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heart Rate (HR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mean Arterial Blood Pressure (MAP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Predicted remifentanil effect‐site concentrations (CeREMI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol effect‐site concentration
Number of subjects: 120
Study: 22696825

Group type: EXPERIMENTAL
Intervention: Rest in the left lateral position (n = 77)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Mild activity (sitting and walking) (n = 75)
Number of subjects: 152
Study: 20167175

Group type: EXPERIMENTAL
Intervention: Veo calibration algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard calibration
Number of subjects: 0
Study: 18690839

Group type: EXPERIMENTAL
Intervention: Elective statin use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All lipid-lowering agents (LLA) use (statin and non-statin LLA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin users
Number of subjects: 0
Study: 15867780

Group type: EXPERIMENTAL
Intervention: Bovine Carpentier‐Edwards Perimount bioprosthesis
Number of subjects: 136

Group type: COMPARATOR
Intervention: Porcine Medtronic Mosaic bioprosthesis
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Bovine Carpentier‐Edwards Perimount bioprosthesis size 23
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Porcine Medtronic Mosaic bioprosthesis size 25
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both bioprostheses
Number of subjects: 136
Study: 12706228

Group type: EXPERIMENTAL
Intervention: Slow repetitive transcranial magnetic stimulation (rTMS) over the striate cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 10574477

Group type: EXPERIMENTAL
Intervention: Growth hormone, oral glutamine, and high-carbohydrate-low-fat (HCLF) diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 8966026

Group type: EXPERIMENTAL
Intervention: LCP-F (formula supplemented with long-chain polyunsaturates)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional infant formula (without long-chain polyunsaturates)
Number of subjects: 22
Study: 1830450

Group type: EXPERIMENTAL
Intervention: Enoximone 100 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Enoximone 25 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6357203

Group type: EXPERIMENTAL
Intervention: cetraxate
Number of subjects: 0

Group type: COMPARATOR
Intervention: aldioxa
Number of subjects: 0
Study: 31483750

Group type: EXPERIMENTAL
Intervention: HPLC-MRM-IDA-EPI analytical method for detecting chemotherapy drugs
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Secondary tandem mass spectrometry approach
Number of subjects: 743
Study: 30325565

Group type: EXPERIMENTAL
Intervention: vNOTES
Number of subjects: 70

Group type: COMPARATOR
Intervention: TLH
Number of subjects: 70
Study: 28234265

Group type: EXPERIMENTAL
Intervention: Nordic Walking training (12 weeks, 3 times a week, 1 hour)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 25568411

Group type: EXPERIMENTAL
Intervention: Removal of subchondral bone plate (SCBP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Retention of subchondral bone plate (SCBP)
Number of subjects: 50
Study: 23292545

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CM)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 208
Study: 22462692

Group type: EXPERIMENTAL
Intervention: TheraTogs (a corset with elasticated strapping) applied to support hip extensor and abductor musculature for 5 weeks or until patients reach Functional Ambulation category 5.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cane walking held at the level of the radial styloid of the sound wrist for 5 weeks or until patients reach Functional Ambulation category 5.
Number of subjects: 120
Study: 19019053

Group type: EXPERIMENTAL
Intervention: Wound perfusion with 8 mL of 0.25% bupivacaine every 5 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous pethidine 0.2 mg/kg on demand
Number of subjects: 50
Study: 17320546

Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resections (LCRs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open colorectal resections (OCRs)
Number of subjects: 40
Study: 15117890

Group type: EXPERIMENTAL
Intervention: GnRH agonist plus raloxifene (leuprolide acetate depot at 3.75 mg/28 days and raloxifene hydrochloride at 60 mg/day for 18 cycles)
Number of subjects: 50
Study: 12200524

Group type: EXPERIMENTAL
Intervention: eformoterol Turbohaler 9 microg (delivered dose)
Number of subjects: 663

Group type: COMPARATOR
Intervention: budesonide Turbohaler 400 microg twice daily
Number of subjects: 663
Study: 9618752

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) up to 0.25 U/kg per week in daily doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 20
Study: 7659635

Group type: EXPERIMENTAL
Intervention: Interactive computer program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Audio tape
Number of subjects: 100
Study: 1837965

Group type: EXPERIMENTAL
Intervention: 0.150 mg Desogestrel and 0.030 mg Ethinylestradiol
Number of subjects: 308

Group type: COMPARATOR
Intervention: 0.075 mg Gestoden and 0.030 mg Ethinylestradiol
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 0.250 mg Norgestimat and 0.035 mg Ethinylestradiol
Number of subjects: 308
Study: 6792566

Group type: EXPERIMENTAL
Intervention: Vulnerable-Experimental group (119 trainees) required to report to the CMHA Early Intervention Program
Number of subjects: 269

Group type: COMPARATOR
Intervention: Vulnerable-Control group (150 trainees) not required to report to the CMHA Early Intervention Program
Number of subjects: 269
Study: 30548252

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 58
Study: 29102044

Group type: EXPERIMENTAL
Intervention: Intramedullary nail
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sliding Hip Screw
Number of subjects: 1000
Study: 25211767

Group type: EXPERIMENTAL
Intervention: Combination hearing aid with noise feature activated (experimental group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hearing aids alone (control group, n=15)
Number of subjects: 30
Study: 24849708

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg (arm A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nintedanib 250 mg (arm B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 81
Study: 23151699

Group type: EXPERIMENTAL
Intervention: Opal self-ligating brackets (SLBs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional standard metal manually ligating brackets (MLBs)
Number of subjects: 14
Study: 19687168

Group type: EXPERIMENTAL
Intervention: Surgery and rhTSH stimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Surgery and l-T(4) abstinence
Number of subjects: 25
Study: 17312403

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) measles vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous (SQ) measles vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both IN and SQ vaccines
Number of subjects: 0
Study: 15498746

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (writing about an emotional topic)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Neutral writing topic (control)
Number of subjects: 106
Study: 11588753

Group type: EXPERIMENTAL
Intervention: MagnaBloc (n = 38)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (n = 26)
Number of subjects: 64